KOREA UNITED PHARM INC
Financials
Valuation Metrics
KOREA UNITED PHARM INC's Market Cap is ₩2566B. At end of 2025 it was ₩3034B. Ranked #657 of 2,410 in KR market (top 27%), #385 of 779 on KOSPI (top 49%), #70 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 30%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 256.64B KRW | KR#657/2,410 Sec#70/231 |
| Revenue | 298.08B KRW | KR#826/2,410 Sec#38/231 |
| Net Income | 76.16B KRW | KR#308/2,410 Sec#23/231 |
| Total Assets | 570.76B KRW | KR#713/2,410 Sec#42/231 |
| Net Assets | 497.12B KRW | KR#516/2,410 Sec#31/231 |
| Employees | 936 | KR#271/2,410 Sec#21/231 |
| Value | ||
| P/E | 3.37x | KR#241/2,410 Sec#8/231 |
| P/B | 0.52x | KR#962/2,410 Sec#52/231 |
| PEG | 0.03x | KR#245/2,410 Sec#15/231 |
| P/S | 0.86x | KR#1,380/2,410 Sec#81/231 |
| EV/EBITDA | 4.61x | KR#266/2,410 Sec#4/231 |
| FCF Yield | 10.79% | KR#633/2,410 Sec#26/231 |
| Profitability | ||
| ROE | 15.32% | KR#311/2,410 Sec#20/231 |
| ROA | 13.34% | KR#156/2,410 Sec#13/231 |
| Op. Margin | 16.64% | KR#246/2,410 Sec#24/231 |
| Revenue Growth | 4.13% | KR#1,249/2,410 Sec#128/231 |
| Earnings Growth | 127.42% | KR#343/2,410 Sec#21/231 |
| Financial Health | ||
| Debt Ratio | 14.81% | KR#241/2,410 Sec#38/231 |
| Total Debt | 13.94B KRW | KR#1,511/2,410 Sec#130/231 |
| FCF | 27.69B KRW | KR#434/2,410 Sec#24/231 |
| Cash | 41.66B KRW | KR#830/2,410 Sec#51/231 |
| Current Ratio | 5.52x | KR#247/2,410 Sec#47/231 |
| Net Debt/EBITDA | -0.56x | KR#473/2,410 Sec#28/231 |
| Dividend | ||
| Div. Yield | 3.78% | KR#562/2,410 Sec#24/231 |
| Div. Growth | 35.56% | KR#320/2,410 Sec#15/231 |
| Performance | ||
| 1Y Return | -15.15% | KR#809/2,410 Sec#47/231 |
| 1M Return | -7.99% | KR#677/2,410 Sec#70/231 |
| From 52W High | -26.01% | KR#221/2,410 Sec#13/231 |
| 1Y MDD | -24.63% | KR#90/2,410 Sec#5/231 |
| Trading | ||
| Volume | 71,249 shares | KR#1,372/2,410 Sec#140/231 |
| Trading Value | 1.15B KRW | KR#851/2,410 Sec#89/231 |
| Foreign Own. | 8.93% | KR#514/2,410 Sec#43/231 |
| Per Share | ||
| EPS | 4,787 KRW | KR#226/2,410 Sec#12/231 |
| BPS | 31,244 KRW | KR#364/2,410 Sec#26/231 |
Company Info
United Pharmaceutical, a specialized pharmaceutical manufacturer established in 1987 for the manufacture and sale of pharmaceuticals, was listed on KOSDAQ in 1999 and re-listed on KOSPI in 2007. Headquartered in Jeondong-myeon, Sejong Special Self-Governing City, the company maintains 7 affiliates including United Interpharm. It sells 18 improved new drugs and new formulation products, such as the antithrombotic treatment 'Silostan CR' (approx. 15% of sales) and the dyslipidemia treatment 'Artmac Combi-Gel' (approx. 10% of sales), to medical institutions and pharmacies nationwide.